Paulo L Lizano1, Jeffrey K Yao2, Neeraj Tandon3, Suraj Sarvode Mothi4, Debra M Montrose5, Matcheri S Keshavan6. 1. Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, United States; Division of Public Psychiatry, Massachusetts Mental Health Center, Boston, MA, United States. 2. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; VA Pittsburgh Healthcare System, Medical Research Service, Pittsburgh, PA, United States; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, United States. Electronic address: jkyao@pitt.edu. 3. Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, United States; Baylor College of Medicine, Houston, TX, United States. 4. Division of Public Psychiatry, Massachusetts Mental Health Center, Boston, MA, United States. 5. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. 6. Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, United States; Division of Public Psychiatry, Massachusetts Mental Health Center, Boston, MA, United States; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States; Department of Psychiatry, Harvard Medical School, Boston, MA, United States. Electronic address: mkeshava@bidmc.harvard.edu.
Abstract
BACKGROUND: Angiogenic dysfunction and abnormalities in psychopathology and brain structure have been reported in schizophrenia, but their relationships are mostly unknown. We recently demonstrated that sFlt-1, anti-angiogenic factor, was significantly elevated in patients at familial high-risk for psychosis (FHR). We hypothesized that elevated sFlt-1 correlates with baseline and longitudinal changes in psychopathology, cognition, and brain structure. METHODS: Plasma sFlt-1 in FHR (n=35) and HC (n=39) was obtained at baseline. Schizotypal, cognitive, soft neurologic signs, and structural brain imaging (1.5T T1-weighted MRI, FreeSurfer software) measures were obtained in both groups. Longitudinal clinical and brain structural measures were obtained in a subgroup of FHR patients. Baseline data analysis used correlations between sFlt-1 and clinical/imaging measures and adjusted for multiple corrections. Linear mixed-effects models described differences in trajectories between high sFlt-1 and low sFlt-1. RESULTS: Baseline sFlt-1 was significantly correlated with soft neurologic signs (r=0.27, p=0.02) and right entorhinal volume (r=0.50, p=0.02), but not other baseline clinical/brain structural measures. Longitudinal examination of the FHR group (sFlt-1 high, n=14; sFlt-1 low, n=14) demonstrated that high sFlt-1 was significantly associated with worsening schizotypal symptoms (t=2.4, p=0.018). Reduced right hippocampal/parahippocampal volume/thickness trajectories were observed in high versus low sFlt-1 groups. CONCLUSIONS: The findings from this FHR study demonstrate that peripheral markers of angiogenic dysfunction can predict longitudinal clinical and brain structural changes. Also, these findings further support the hypothesis of altered microvascular circulation in schizophrenia and those at risk. Published by Elsevier B.V.
BACKGROUND:Angiogenic dysfunction and abnormalities in psychopathology and brain structure have been reported in schizophrenia, but their relationships are mostly unknown. We recently demonstrated that sFlt-1, anti-angiogenic factor, was significantly elevated in patients at familial high-risk for psychosis (FHR). We hypothesized that elevated sFlt-1 correlates with baseline and longitudinal changes in psychopathology, cognition, and brain structure. METHODS: Plasma sFlt-1 in FHR (n=35) and HC (n=39) was obtained at baseline. Schizotypal, cognitive, soft neurologic signs, and structural brain imaging (1.5T T1-weighted MRI, FreeSurfer software) measures were obtained in both groups. Longitudinal clinical and brain structural measures were obtained in a subgroup of FHR patients. Baseline data analysis used correlations between sFlt-1 and clinical/imaging measures and adjusted for multiple corrections. Linear mixed-effects models described differences in trajectories between high sFlt-1 and low sFlt-1. RESULTS: Baseline sFlt-1 was significantly correlated with soft neurologic signs (r=0.27, p=0.02) and right entorhinal volume (r=0.50, p=0.02), but not other baseline clinical/brain structural measures. Longitudinal examination of the FHR group (sFlt-1 high, n=14; sFlt-1 low, n=14) demonstrated that high sFlt-1 was significantly associated with worsening schizotypal symptoms (t=2.4, p=0.018). Reduced right hippocampal/parahippocampal volume/thickness trajectories were observed in high versus low sFlt-1 groups. CONCLUSIONS: The findings from this FHR study demonstrate that peripheral markers of angiogenic dysfunction can predict longitudinal clinical and brain structural changes. Also, these findings further support the hypothesis of altered microvascular circulation in schizophrenia and those at risk. Published by Elsevier B.V.
Entities:
Keywords:
Angiogenesis; Brain structure; Genetic high risk for psychosis; Longitudinal study; Microvascular; Soluble fms-like tyrosine kinase
Authors: Vaibhav A Diwadkar; Debra M Montrose; Diana Dworakowski; John A Sweeney; Matcheri S Keshavan Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2005-11-28 Impact factor: 5.067
Authors: M T Rätsep; A Paolozza; A F Hickman; B Maser; V R Kay; S Mohammad; J Pudwell; G N Smith; D Brien; P W Stroman; M A Adams; J N Reynolds; B A Croy; N D Forkert Journal: AJNR Am J Neuroradiol Date: 2015-12-31 Impact factor: 3.825
Authors: Lei Cao; Xiangyang Jiao; David S Zuzga; Yuhong Liu; Dahna M Fong; Deborah Young; Matthew J During Journal: Nat Genet Date: 2004-07-18 Impact factor: 38.330
Authors: H W Thermenos; M S Keshavan; R J Juelich; E Molokotos; S Whitfield-Gabrieli; B K Brent; N Makris; L J Seidman Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2013-10 Impact factor: 3.568
Authors: Alissa R Carver; Maria Andrikopoulou; Jun Lei; Esther Tamayo; Phyllis Gamble; Zhipeng Hou; Jiangyang Zhang; Susumu Mori; George R Saade; Maged M Costantine; Irina Burd Journal: PLoS One Date: 2014-06-25 Impact factor: 3.240
Authors: Deepthi Bannai; Iniya Adhan; Raviv Katz; Leo A Kim; Matcheri Keshavan; John B Miller; Paulo Lizano Journal: Schizophr Bull Date: 2022-01-21 Impact factor: 7.348
Authors: Deepthi Bannai; Paulo Lizano; Megan Kasetty; Olivia Lutz; Victor Zeng; Suraj Sarvode; Leo A Kim; Scot Hill; Carol Tamminga; Brett Clementz; Elliot Gershon; Godfrey Pearlson; John B Miller; Matcheri Keshavan Journal: Psychiatry Res Neuroimaging Date: 2020-02-29 Impact factor: 2.376
Authors: Paulo Lizano; Olivia Lutz; Yanxun Xu; Leah H Rubin; Lyle Paskowitz; Adam M Lee; Seenae Eum; Sarah K Keedy; S Kristian Hill; James L Reilly; Baolin Wu; Carol A Tamminga; Brett A Clementz; Godfrey D Pearlson; Elliot S Gershon; Matcheri S Keshavan; John A Sweeney; Jeffrey R Bishop Journal: Mol Psychiatry Date: 2020-10-15 Impact factor: 13.437